Jirsak / shutterstock.com
The US District Court for the District of Massachusetts has issued a ruling on a summary judgment motion filed by Celltrion Healthcare and Hospira, invalidating a Janssen patent related to Remicade (infliximab).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
USPTO patent, Janssen, Celltrion, Hospira, Remicade, infliximab